Illumina (NASDAQ:ILMN) Reaches New 12-Month High - Should You Buy?

Key Points

• Illumina shares reached a new 52-week high, trading as high as $210.93 and last changing hands near $211.89, up 3.3% from the prior close.
• Analyst sentiment is mixed: several firms raised price targets and issued buy or outperform ratings, but MarketBeat’s overall consensus remains “Hold” with a $188.40 target price—below the current share price.
• Illumina recently beat quarterly expectations, reporting $1.31 in earnings per share and $1.16 billion in revenue, while revenue rose 9.4% year over year. However, insiders sold more than $255 million of stock over the past 90 days.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $210.93 and last traded at $211.8860, with a volume of 197905 shares changing hands. The stock had previously closed at $205.00.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent research reports. Royal Bank Of Canada increased their target price on shares of Illumina from $170.00 to $230.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. TD Cowen raised their price objective on shares of Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Sanford C. Bernstein restated a "market perform" rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Finally, Leerink Partners boosted their target price on Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of "Hold" and a consensus target price of $188.40.

Illumina Stock Up 3.3%

The stock has a market capitalization of $31.99 billion, a price-to-earnings ratio of 39.52, a PEG ratio of 2.65 and a beta of 1.45. The firm's fifty day moving average is $185.90 and its 200-day moving average is $151.49. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company earned $1.19 earnings per share. The business's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 615 shares of the business's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider owned 20,338 shares of the company's stock, valued at $4,067,600. The trade was a 2.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the business's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last 90 days. Insiders own 2.90% of the company's stock.

Institutional Investors Weigh In On Illumina

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC acquired a new position in shares of Illumina in the 4th quarter valued at approximately $25,000. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Fiduciary Financial Advisors bought a new stake in shares of Illumina during the 2nd quarter worth approximately $26,000. Finally, Activest Wealth Management raised its position in Illumina by 671.9% during the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source